📈   Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Health

Cytokinetics, Incorporated (NASDAQ:CYTK) is gearing up to complete its rolling NDA submission of aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy [oHCM] in Q3 of 2024. This presents itself as an opportunity because the announcement of the completion of such a rolling submission could yield a higher stock price. Not only that, but from there if the FDA accepts this regulatory application for review, this sets up the ability for an established PDUFA date for review of aficamten for the treatment of this patient population. However, why investors should care about this biotech because there are two pathways to consider for advancement.

seekingalpha.com     Aug 13, 2024